申请人:JANSSEN PHARMACEUTICA NV
公开号:US09266835B2
公开(公告)日:2016-02-23
The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
本发明涉及喹啉衍生物、含有该衍生物的药物组合物及其在治疗由CB-1受体介导的疾病和症状中的应用;更具体地,在治疗对CB-1受体的反向激动作用有响应的疾病和症状中的应用。例如,本发明的化合物在治疗代谢性疾病方面是有用的。